Research programme: CNS disorders therapeutics - Argenta/Lundbeck
Alternative Names: AA 21279; Lu AA21279; NK3 receptor antagonists - LundbeckLatest Information Update: 10 Apr 2014
At a glance
- Originator Lundbeck A/S
- Developer Argenta; Lundbeck A/S
- Class Acetic acids; Small molecules
- Mechanism of Action Glycine reuptake inhibitors; Neurokinin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders; Schizophrenia
Most Recent Events
- 10 Apr 2014 Discontinued - Preclinical for CNS disorders in Europe (unspecified route)
- 10 Apr 2014 Discontinued - Preclinical for Schizophrenia in Europe (unspecified route)
- 31 Mar 2014 Argenta has been acquired by Charles River Laboratories